Multiple MyelomaNCT04039100
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
A study testing Family Caregiver Ambassador Support in people with Multiple Myeloma and Lymphoma, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
Trial summary
Background: Family caregivers are of great importance to patients undergoing treatment for cancer, but at the same time, caregivers themselves are in great risk of distress and high symptom burden which affects their quality of life and ability to support the patients. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Multiple Myeloma, Lymphoma, Bone Marrow Transplantation
- What is being tested?
- Family Caregiver Ambassador Support
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Oct 2019to 1 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Eligible family caregivers (FC) are ≥ 18 years old and a family member or significant other of a patient with hematological malignancy in one of three categories: 1) acute: newly diagnosed with acute leukemia/high risk myelodysplastic syndrome (MDS) or lymphoma ≤ 4 weeks from diagnosis who will receive intensive chemotherapy (n=10), 2) chronic: diagnosed with myeloma or chronic leukemia/MDS or lymphoma to receive less intensive chemotherapy or palliation (n=10) and 3) complex course of treatment: to undergo a stem cell transplantation (n=10).
- Eligible Family Caregiver Ambassadors (FCA) are ≥18 years old and a family caregiver of a survivor of a patient with hematological malignancy (in complete remission) and provides consent to participate in the ambassador training program. Informed written consent will be provided by all participants
Who cannot join
- Participants (FC and FCA) will be excluded if they do not understand, read and speak Danish, if they have unstable medical disease or cognitive/psychiatric disorders
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (FAM CARE) - a Feasibility Study
Background: Family caregivers are of great importance to patients undergoing treatment for cancer, but at the same time, caregivers themselves are in great risk of distress and high symptom burden which affects their quality of life and ability to support the patients. Within hematology the context of treatment from hospital to home has changed in the past years placing more responsibilities on caregivers. Finding new ways to support caregivers within the health care context is important. Psychosocial interventions can enhance emotional well-being, and peer to peer support model has been found to be effective for patients coping with cancer. There is a lack of knowledge and evidence of the feasibility and effects of a peer-to-peer support in caregivers within hematology.
Aims: The study aim to examine the feasibility and safety of Family Caregiver Ambassador Support in caregivers of newly diagnosed patients with hematological disease, and to examine if it has an effects on symptoms and psychological wellbeing in both family caregivers and ambassadors. It is hypothesized that the family caregiver peer to peer support model will reduce symptoms of burden, reduce concerns and improve emotional and social well-being in family caregivers.
Read more
Design and methods: The study is a one arm feasibility intervention trial with family caregivers (n=30) and family caregiver ambassadors (N=20). Family Caregivers will be recruited at the Department of Hematology, Rigshospitalet. Family Caregivers will be partnered with a family caregiver ambassador. The intervention will be carried out in a 12-week period and consist of telephone and/or e-mail contact and face to face meetings with one follow-up at three months. Both caregiver and ambassador data will be collected at baseline, post intervention and follow-up 3 months.
Implication: The study has the potential to be a new model of care incorporated in the clinical setting to strengthen the support system for caregivers and may likely be tailored to other cancer groups and caregivers.
Read the detailed description
Aim: To investigate whether a Family Caregiver Support Model intervention (FAM-CARE) is feasible and safe, and the impact on the caregiving role and psychosocial wellbeing in family caregivers of newly diagnosed patients with hematological malignancies, and former caregivers (family caregiver ambassadors).
Design and Methods: This study is a one arm feasibility 12-week intervention trial including family caregivers (FC) (n=30) and family caregiver ambassadors (FCA)(n=20).
Recruitment: FC will be recruited at the Department of Hematology, Rigshospitalet (RH). Eligible family caregivers will receive oral and written information on the project from main investigator Iben Husted Nielsen (IHN) within four weeks from the patients' diagnosis. Due to ethical considerations and data protection guidelines patients of eligible caregivers will be approached by IHN with permission to contact their caregivers before approaching them. Family caregivers will be given information on the study and the opportunity to raise questions and concerns and time to consider before enrollment.
FCA will be recruited voluntarily from the Department of Hematology, RH and patient associations (LyLe, Myeloma). The FCA is screened by IHN to assess their appropriateness for the intervention with interview questions regarding their motivation, availability, and vulnerability. They will be asked to sign a confidentiality commitment. The FCA will be informed that they must provide transportation but will receive a monetary incentive for their participation. Further FCA will be asked to provide information regarding age, gender, interests, work, education and social conditions and family role in order to match with the FC. FC and FCA will be matched according to their preferences i.e. patient diagnosis, age, gender and other factors that might create a mutual understanding and ease communication. Given the preferences cannot be granted, the FC and FCA will be involved in the decision.
FAM CARE Intervention: The intervention consists of individual support provided by the FCA to the FC, with minimum four face-to-face meetings between the FC and FCA, and with ad hoc telephone and/or email contact based on the FC's individual needs, and one follow-up telephone contact at 3 months. The place of meeting and purpose of each face-to-face meeting is agreed upon by the FC and FCA. The FCA will follow one FC at a time, however at the end of the 12- week period the FCA can choose to follow a new FC. Upon the first meeting and expectation agreement will be discussed between the FC and FCA. During the intervention the FCA will document the frequency of meetings, duration, place, content and quality of the interactions between FC and FCA.
Recruited FCA's will receive a six-hour group education and training program prior to interacting with FC. The training program include important and relevant actions and information on the role as ambassador, communication skills with emphasis on active listening, and discussion about volunteering and how to maintain appropriate boundaries to ensure that FCA are aware of their role as listeners who share their experiences only when solicited by the FC. The training will be organized by IHN and a project nurse and carried out by IHN, the project nurse and a project psychologist. To secure the safety of FCA during the intervention they will be offered to attend support meetings organized by IHN and the project psychologist to process and share their experiences with being an ambassador. Support meetings will be held every second month and FCA can request individual supervision from the project psychologist during the intervention. Any severe adverse events will be documented and acted upon.
Outcome measures and data collection: Data are collected by patient reported outcome measures (PROM) as self-reported questionnaires completed by FC electronically prior to intervention, post intervention (12-weeks) and at 3-month follow-up. PROM is completed by FCA prior to intervention and at post intervention (12 weeks). Socio-demographic data are collected by questionnaire. At the end of the 3-months follow-up focus group interviews with FC and FCA will be conducted on their experiences.
- Conditions
- Multiple Myeloma, Lymphoma, Bone Marrow Transplantation, Neoplasms, Hematologic Diseases, Leukemia, Myeloid
- Being tested
- Family Caregiver Ambassador Support
- Keywords
- Peer to Peer, Psychosocial Support, Caregivers
- Medical subject headings
- Multiple Myeloma, Lymphoma, Neoplasms, Hematologic Diseases, Leukemia, Myeloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Family Caregiver Ambassador SupportOther
Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Family Caregiver Ambassador Support | Experimental | Intervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20) Receives: Other: Family Caregiver Ambassador Support |
What is being measured
The primary outcome is the main question the study is designed to answer.
Recruitment rate
Number of participants included from eligible family caregivers
Measured: Up to 2 years
Adherence to intervention
Number of weeks completed out of planned weeks of intervention
Measured: up to 24 weeks
Emotional reactions (quality of contacts)
Registration on descriptive data on content of contacts with project team members (primary investigator/project psychologist/project nurse)
Measured: up to 24 weeks
Emotional reactions (numbers of contacts)
Registration on numbers of contacts with project team members (primary investigator/project psychologist/project nurse)
Measured: up to 24 weeks
Secondary outcomes (9)
Depression
Measured with the Hospital Anxiety and Depression Scale (HADS)
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Anxiety
Measured with the Hospital Anxiety and Depression Scale (HADS)
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Sleep
Measured with the Pittsburgh Sleep Quality Index (PSQI)
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Health-related quality of life
Measured with the Short form-36 (SF-36)
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Self-efficacy
Measured with the General Self-Efficacy Scale questionnaire. Scale ranges with total scores (higher scores indicating better self-efficacy)
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Caregiver roles and responsibilities
Measured with the Caregiver Roles and Responsibilities Scale (CRRS) questionnaire measuring cancer impact on the lives of caregivers, each subscale provided by total scores
Measured: Change measures (baseline, 12 weeks, 24 weeks)
Number of contacts between family caregiver and ambassador
Measured by the total number of contacts during the planned weeks of intervention.
Measured: Up to 12 weeks
Length of contacts between family caregiver and ambassador
Measured by the total time of contacts during the planned weeks of
Measured: Up to 12 weeks
Thematic content of the contacts between family caregiver and ambassador
Measured by ambassadors registrations and descriptions of thematic content of the contacts with the family caregiver
Measured: Up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2019
- Study start1 Oct 2019
- Primary completion1 Jul 2021
- Study completion1 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Multiple MyelomaStudies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Iben Husted Nielsen, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Mary Jarden, ph.d., Study director, Copenhagen University Hospital, Rigshospitalet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04039100
- Sponsor's protocol ID
- FAM CARE
- Status last verified
- Feb 2022
- First submitted
- 29 Jul 2019
- Last updated
- 8 Feb 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Noerskov KH, Nielsen IH, Rahbaek ES, Halbro S, Mortensen AO, Overgaard UM, Piil K, Jarden M. Implementation and Evaluation of Peer Ambassador Support to Patients Newly Diagnosed With Hematological Cancer and Their Caregivers. Nurs Res Pract. 2025 Apr 28;2025:4528051. doi: 10.1155/nrp/4528051. eCollection 2025.
PubMed 40330711Husted Nielsen I, Piil K, Tolver A, Gronbaek K, Kjeldsen L, Jarden M. Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study. Support Care Cancer. 2022 Aug;30(8):6923-6935. doi: 10.1007/s00520-022-07089-0. Epub 2022 May 11.
PubMed 35543814
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease (FAM CARE) - a Feasibility Study
- ClinicalTrials.gov ID
- NCT04039100
- Acronym / sponsor ID
- FAM CARE
- Conditions
- Multiple Myeloma, Lymphoma, Bone Marrow Transplantation, Neoplasms, Hematologic Diseases, Leukemia, Myeloid
- Keywords
- Peer to Peer, Psychosocial Support, Caregivers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 1 Jul 2021 (actual)
- Study completion
- 1 Dec 2021 (actual)
- First posted
- 31 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Family caregivers are of great importance to patients undergoing treatment for cancer, but at the same time, caregivers themselves are in great risk of distress and high symptom burden which affects their quality of life and ability to support the patients. Within hematology the context of treatment from hospital to home has changed in the past years placing more responsibilities on caregivers. Finding new ways to support caregivers within the health care context is important. Psychosocial interventions can enhance emotional well-being, and peer to peer support model has been found to be effective for patients coping with cancer. There is a lack of knowledge and evidence of the feasibility and effects of a peer-to-peer support in caregivers within hematology.
Aims: The study aim to examine the feasibility and safety of Family Caregiver Ambassador Support in caregivers of newly diagnosed patients with hematological disease, and to examine if it has an effects on symptoms and psychological wellbeing in both family caregivers and ambassadors. It is hypothesized that the family caregiver peer to peer support model will reduce symptoms of burden, reduce concerns and improve emotional and social well-being in family caregivers.
Design and methods: The study is a one arm feasibility intervention trial with family caregivers (n=30) and family caregiver ambassadors (N=20). Family Caregivers will be recruited at the Department of Hematology, Rigshospitalet. Family Caregivers will be partnered with a family caregiver ambassador. The intervention will be carried out in a 12-week period and consist of telephone and/or e-mail contact and face to face meetings with one follow-up at three months. Both caregiver and ambassador data will be collected at baseline, post intervention and follow-up 3 months.
Implication: The study has the potential to be a new model of care incorporated in the clinical setting to strengthen the support system for caregivers and may likely be tailored to other cancer groups and caregivers.
Detailed description
Aim: To investigate whether a Family Caregiver Support Model intervention (FAM-CARE) is feasible and safe, and the impact on the caregiving role and psychosocial wellbeing in family caregivers of newly diagnosed patients with hematological malignancies, and former caregivers (family caregiver ambassadors).
Design and Methods: This study is a one arm feasibility 12-week intervention trial including family caregivers (FC) (n=30) and family caregiver ambassadors (FCA)(n=20).
Recruitment: FC will be recruited at the Department of Hematology, Rigshospitalet (RH). Eligible family caregivers will receive oral and written information on the project from main investigator Iben Husted Nielsen (IHN) within four weeks from the patients' diagnosis. Due to ethical considerations and data protection guidelines patients of eligible caregivers will be approached by IHN with permission to contact their caregivers before approaching them. Family caregivers will be given information on the study and the opportunity to raise questions and concerns and time to consider before enrollment.
FCA will be recruited voluntarily from the Department of Hematology, RH and patient associations (LyLe, Myeloma). The FCA is screened by IHN to assess their appropriateness for the intervention with interview questions regarding their motivation, availability, and vulnerability. They will be asked to sign a confidentiality commitment. The FCA will be informed that they must provide transportation but will receive a monetary incentive for their participation. Further FCA will be asked to provide information regarding age, gender, interests, work, education and social conditions and family role in order to match with the FC. FC and FCA will be matched according to their preferences i.e. patient diagnosis, age, gender and other factors that might create a mutual understanding and ease communication. Given the preferences cannot be granted, the FC and FCA will be involved in the decision.
FAM CARE Intervention: The intervention consists of individual support provided by the FCA to the FC, with minimum four face-to-face meetings between the FC and FCA, and with ad hoc telephone and/or email contact based on the FC's individual needs, and one follow-up telephone contact at 3 months. The place of meeting and purpose of each face-to-face meeting is agreed upon by the FC and FCA. The FCA will follow one FC at a time, however at the end of the 12- week period the FCA can choose to follow a new FC. Upon the first meeting and expectation agreement will be discussed between the FC and FCA. During the intervention the FCA will document the frequency of meetings, duration, place, content and quality of the interactions between FC and FCA.
Recruited FCA's will receive a six-hour group education and training program prior to interacting with FC. The training program include important and relevant actions and information on the role as ambassador, communication skills with emphasis on active listening, and discussion about volunteering and how to maintain appropriate boundaries to ensure that FCA are aware of their role as listeners who share their experiences only when solicited by the FC. The training will be organized by IHN and a project nurse and carried out by IHN, the project nurse and a project psychologist. To secure the safety of FCA during the intervention they will be offered to attend support meetings organized by IHN and the project psychologist to process and share their experiences with being an ambassador. Support meetings will be held every second month and FCA can request individual supervision from the project psychologist during the intervention. Any severe adverse events will be documented and acted upon.
Outcome measures and data collection: Data are collected by patient reported outcome measures (PROM) as self-reported questionnaires completed by FC electronically prior to intervention, post intervention (12-weeks) and at 3-month follow-up. PROM is completed by FCA prior to intervention and at post intervention (12 weeks). Socio-demographic data are collected by questionnaire. At the end of the 3-months follow-up focus group interviews with FC and FCA will be conducted on their experiences.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Family Caregiver Ambassador Support | Experimental | Other: Family Caregiver Ambassador SupportIntervention group: caregivers of newly diagnosed patients (n=30), former family caregivers as ambassadors (n=20) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Eligible family caregivers (FC) are ≥ 18 years old and a family member or significant other of a patient with hematological malignancy in one of three categories: 1) acute: newly diagnosed with acute leukemia/high risk myelodysplastic syndrome (MDS) or lymphoma ≤ 4 weeks from diagnosis who will receive intensive chemotherapy (n=10), 2) chronic: diagnosed with myeloma or chronic leukemia/MDS or lymphoma to receive less intensive chemotherapy or palliation (n=10) and 3) complex course of treatment: to undergo a stem cell transplantation (n=10).
- Eligible Family Caregiver Ambassadors (FCA) are ≥18 years old and a family caregiver of a survivor of a patient with hematological malignancy (in complete remission) and provides consent to participate in the ambassador training program. Informed written consent will be provided by all participants
Key exclusion criteria (1 listed)
- Participants (FC and FCA) will be excluded if they do not understand, read and speak Danish, if they have unstable medical disease or cognitive/psychiatric disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Family Caregiver Ambassador SupportFamily Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks | Other | Family Caregiver Ambassador Support |
Primary outcome
Recruitment rate
Time frame: Up to 2 years
Number of participants included from eligible family caregivers
Adherence to intervention
Time frame: up to 24 weeks
Number of weeks completed out of planned weeks of intervention
Emotional reactions (quality of contacts)
Time frame: up to 24 weeks
Registration on descriptive data on content of contacts with project team members (primary investigator/project psychologist/project nurse)
Emotional reactions (numbers of contacts)
Time frame: up to 24 weeks
Registration on numbers of contacts with project team members (primary investigator/project psychologist/project nurse)
9 secondary outcomes
Depression
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Anxiety
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Sleep
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Health-related quality of life
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Self-efficacy
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Caregiver roles and responsibilities
Time frame: Change measures (baseline, 12 weeks, 24 weeks)
Number of contacts between family caregiver and ambassador
Time frame: Up to 12 weeks
Length of contacts between family caregiver and ambassador
Time frame: Up to 12 weeks
Thematic content of the contacts between family caregiver and ambassador
Time frame: Up to 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2022.
- Derived from this study: PubMed 40330711Noerskov KH, Nielsen IH, Rahbaek ES, Halbro S, Mortensen AO, Overgaard UM, Piil K, Jarden M. Implementation and Evaluation of Peer Ambassador Support to Patients Newly Diagnosed With Hematological Cancer and Their Caregivers. Nurs Res Pract. 2025 Apr 28;2025:4528051. doi: 10.1155/nrp/4528051. eCollection 2025.
- Derived from this study: PubMed 35543814Husted Nielsen I, Piil K, Tolver A, Gronbaek K, Kjeldsen L, Jarden M. Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study. Support Care Cancer. 2022 Aug;30(8):6923-6935. doi: 10.1007/s00520-022-07089-0. Epub 2022 May 11.
- Individual participant dataSharing planned: No
Related trials for Multiple Myeloma
Not yet recruitingPhase 2
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Active, not recruitingPhase 3
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Multiple Myeloma
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mary Jarden, ph.d. study director
Copenhagen University Hospital, Rigshospitalet
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Family Caregiver Ambassador Support in people with Multiple Myeloma and Lymphoma, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Recruitment rate (time frame: Up to 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04039100, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2022.